Skip to main content
Daan Gene Co., Ltd. logo

Daan Gene Co., Ltd. — Investor Relations & Filings

Ticker · 002030 ISIN · CNE000001KP1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,189 across all filing types
Latest filing 2025-05-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002030

About Daan Gene Co., Ltd.

https://www.daangene.com

Daan Gene Co., Ltd. specializes in the development and manufacturing of molecular diagnostic products and services. The company focuses on in vitro diagnostic technologies, particularly polymerase chain reaction (PCR) platforms. Its product portfolio includes diagnostic kits for infectious diseases, genetic screening, and oncology, alongside automated nucleic acid extraction systems and real-time PCR instruments. Daan Gene provides comprehensive solutions for clinical laboratories and public health institutions, integrating research, production, and clinical testing services. The organization emphasizes technological innovation in molecular biology to support precision medicine and disease control.

Recent filings

Filing Released Lang Actions
上市公司独立董事提名人声明与承诺（侯向京）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by a nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There are no financial statements, earnings data, or report summaries. The content focuses on board/management information, specifically about director nomination and related compliance. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4689 characters, which is sufficient for a detailed statement but not a full report like an annual or interim report.
2025-05-09 Chinese
第八届董事会2025年第三次临时会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of resolutions passed at the 2025 third extraordinary meeting of the eighth board of directors of Guangzhou Da An Gene Co., Ltd. It includes voting results, candidate nominations for the ninth board of directors, and detailed biographies of the nominated directors. The content focuses on board member nominations, voting outcomes, and related procedural details. There is no financial data, earnings information, or audit content. The document is not a report itself but an official announcement of board decisions and nominations. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-05-09 Chinese
上市公司独立董事候选人声明与承诺（范建兵）
Board/Management Information Classification · 100% confidence The document is a detailed declaration and commitment statement by an independent director candidate for Guangzhou Da An Gene Co., Ltd. It includes multiple attestations regarding the candidate's qualifications, independence, compliance with laws and regulations, and commitments to fulfill the duties of an independent director. There are no financial statements, earnings data, or report summaries present. The content is related to board/management information, specifically about a candidate for the board of directors. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2025-05-09 Chinese
关于全资子公司收到现金分红款的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (515 characters) regarding a cash dividend received by a wholly-owned subsidiary from an investee company, based on the investee's annual general meeting profit distribution resolution. It states the dividend amount and its impact on the consolidated net profit. There is no detailed financial report or comprehensive financial data presented. The document is an announcement of dividend receipt, not a full dividend notice to shareholders or a full financial report. Given the short length and nature, it fits best as a Regulatory Filing (RNS) rather than a Notice of Dividend Amount (DIV), which typically announces dividends declared by the company itself to its shareholders. This is a disclosure of dividend income received from an investment, so RNS is appropriate.
2025-05-05 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "广州达安基因股份有限公司2025 年第一季度报告" which translates to "Guangzhou Daan Gene Co., Ltd. 2025 First Quarter Report." It contains detailed financial data including balance sheets, income statements, cash flow statements, and notes on financial performance for the first quarter of 2025. The document includes comprehensive financial figures, accounting data, and management assurances about the accuracy of the report. It explicitly states it is a quarterly report and is unaudited. The length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2025-04-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Da An Gene Co., Ltd. regarding the approval of the company's 2025 first quarter report and the reappointment of the auditing firm for the 2025 fiscal year. It includes voting results and references the full quarterly report being available on the company's disclosure website and in newspapers. The document itself is short (1194 characters) and primarily announces the approval and related decisions rather than containing the full quarterly financial data or detailed analysis. According to the 'Menu vs Meal' rule, this is an announcement of the report and related decisions, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2025-04-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.